Skip to main content

Table 1 Baseline clinical and blood characteristics

From: Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome

Variable

L-C

(n = 89)

Placebo

(n = 88)

Total Cohort

(n = 177)

Age (years), mean ± SD

66.5 ± 8.2

66.3 ± 8.3

66.4 ± 8.2

Sex (male), N (%)

59 (66.3)

65 (73.9)

124 (70.1)

Race/ethnicity (Caucasian), N (%)

87 (97.8)

87 (98.9)

174 (98.3)

WC (cm), mean ± SD

111.6 ± 12.8

112.8 ± 12.0

112.2 ± 12.4

Waist: Hip ratio, mean ± SD

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.1

BMI (kg/m2), mean ± SD

32.2 ± 5.7

32.5 ± 5.2

32.4 ± 5.4

Current smoker, N (%)

12 (13.5)

8 (9.1)

20 (11.3)

HDL-C (mmol/L), median [IQR]

1.1 [0.9 to 1.3]

1.1 [1.0 to 1.3]

1.1 [1.0 to 1.3]

Triglycerides (mmol/L), median [IQR]

1.3 [0.9 to 1.8]

1.4 [0.9 to 1.9]

1.4 [0.9 to 1.9]

Glucose (mmol/L), median [IQR]

6.0 [5.2 to 7.2]

5.9 [5.2 to 6.7]

6.0 [5.2 to 7.0]

HbA1C (%), median [IQR]

6.2 [5.9 to 7.3]

6.5 [5.8 to 7.0]

6.4 [5.9 to 7.1]

eGFR (mL/min/1.73 m2), mean ± SD

83.3 ± 17.0

80.7 ± 17.0

82.0 ± 17.0

Systolic BP (mmHg), mean ± SD

130.5 ± 18.1

132.6 ± 18.8

131.5 ± 18.4

Diastolic BP (mmHg), mean ± SD

76.1 ± 10.1

78.1 ± 10.5

77.1 ± 10.4

Total of MetS criteria

   

 3, N (%)

24 (27.0)

20 (22.7)

44 (24.9)

 4, N (%)

45 (50.6)

47 (53.4)

92 (52.0)

 5, N (%)

20 (22.5)

21 (23.9)

41 (23.2)

Weekly consumed servings of red meat, mean ± SD

2.9 ± 2.9

2.8 ± 2.3

2.8 ± 2.6

  1. p values are not presented due to the nature of randomization. For HDL-C, to convert from mmol/L to mg/dL, multiply by 38.67. For triglycerides, to convert from mmol/L to mg/dL, multiply by 88.57
  2. BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; L-C, L-carnitine; MetS, metabolic syndrome, WC, waist circumference